TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Telix Pharmaceuticals ( (AU:TLX) ) has issued an update.
Telix Pharmaceuticals reported a significant revenue increase of 53% year-over-year for Q3 2025, reaching $206 million, and upgraded its FY 2025 revenue guidance to $800-820 million. The company achieved full reimbursement for Gozellix in the U.S. and expanded its Illuccix product approval to 19 European markets. These developments, along with ongoing clinical trials and strategic market launches, position Telix strongly in the precision medicine sector, enhancing its competitive edge and operational capabilities.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$24.25 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals is a biopharmaceutical company operating in the precision medicine industry, focusing on developing diagnostic and therapeutic products for oncology. The company is known for its PSMA imaging agents, Illuccix and Gozellix, which are used in prostate cancer diagnosis and treatment. Telix is expanding its market presence with approvals in multiple European countries and the U.S., and is actively involved in clinical trials for various cancer therapies.
Average Trading Volume: 2,956,032
Technical Sentiment Signal: Sell
Current Market Cap: A$5.11B
For an in-depth examination of TLX stock, go to TipRanks’ Overview page.